Agency Leadership

White House Withdraws Heidi Overton's FDA Nomination

By Finks Desk
White House Withdraws Heidi Overton's FDA Nomination

For drug and device investors, the biggest approval decision this week was a withdrawal. The White House pulled Heidi Overton's nomination to run the Food and Drug Administration late Tuesday, hours before the Senate health committee vote meant to settle it.

The result is an agency with no Senate-confirmed commissioner and, for now, no replacement nominee. The FDA regulates products that account for about 20% of US consumer spending, and every new medicine, device and labeling change clears through it.

An acting chief can still sign approvals, so the pipeline does not freeze. What changes is discretion: the close calls sit nearer to the Health and Human Services secretary, Robert F. Kennedy Jr., and the Make America Healthy Again priorities.

Approvals are still flowing

Output has held up. The FDA's drug evaluation center approved 46 novel drugs in 2025 and has cleared 50 through Nov. 13 of this year, according to its own tallies. That is more than all of last year, with seven weeks left.

2026 Is Already Past Last Year's Novel Drug Approvals

CDER novel drug approvals, 2025 full year versus 2026 through Nov 13, count of drugs

Bar chart. Novel drug approvals. 2025 full year: Novel drug approvals 46. 2026 through Nov 13: Novel drug approvals 50.

Source: FDA CDER Novel Drug Approvals, 2025 and 2026

Staffing is the softer constraint. Since Trump took office, roughly 20% of the agency's staff has departed through layoffs, buyouts, retirements and resignations, which bears on how fast reviewers clear files. Timing is the part of pipeline risk an approval count does not capture.

The clock is the actual risk

Kyle Diamantas has led the FDA on an acting basis since Marty Makary was forced out in May. Federal rules cap an acting agency head at roughly seven months, and his clock started in May.

Senator Roger Marshall of Kansas, a doctor who lost his reelection bid this month, wants the post. Any confirmed commissioner would have to clear a narrow window before Democrats take control of the Senate in January, after which Cassidy said it falls to them.

One pending decision carries product risk: the FDA is reviewing mifepristone's safety at Trump's request and has promised findings by March, a review that could reinstate restrictions including in-person prescribing.

Why the nomination failed

Overton, a physician and White House domestic policy aide, was nominated in August. Democrats questioned her independence, anti-abortion groups pressed her on mifepristone, and Make America Healthy Again activists treated her as an obstacle to Kennedy's agenda. Republican senators pressed her on childhood vaccine recommendations and flavored e-cigarettes; Cassidy called the vaccine role almost disqualifying.

The withdrawal leaves the agency's 2026 agenda, from food additives to vaccine policy, with an acting chief who has less standing to push back. For investors, that argues for pricing policy risk rather than approval risk into drug and device names until a permanent commissioner is seated.

Even an FDA approval the stock already priced in carries more risk when the referee is temporary.